INBRX-106

DRUG3 trials

Sponsors

Inhibrx Biosciences Inc., Inhibrx Biosciences, Inc, Providence Health & Services

Conditions

Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC)Triple Negative Breast Cancer

Phase 2

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Active, not recruitingNCT06295731

Inhibrx Biosciences, IncHead and Neck Squamous Cell Carcinoma (HNSCC)

Start: 2024-05-14End: 2029-05-01Target: 410Updated: 2026-03-31

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

RecruitingNCT06353997

Providence Health & ServicesTriple Negative Breast Cancer

Start: 2024-09-05End: 2029-06-30Target: 12Updated: 2026-01-15

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)

RecruitingCTIS2024-515538-34-00

Inhibrx Biosciences Inc.Head and Neck Squamous Cell Carcinoma

Start: 2025-02-27Target: 175Updated: 2025-10-08

Related Papers

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058

The Journal of Immunology2025-11-01

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Journal of Clinical Oncology2025-05-28